RxSight anticipates $140M to $160M 2026 revenue as Alcon collaboration adds $30M to $40M
Seeking Alpha ·
Earnings Call Insights: RxSight (RXST) Q2 2026 “Over the last several years, the RxSight team has been developing proprietary hybrid IOL materials for next-generation light adjustable technology that can support a full suite of adjustable lenses across all premium
DYAX Investor Sentiment
Bullish (Long) 50% · Bearish (Short) 50%
470 participants
Related News
- AbbVie, Genmab granted EU label expansion for Tepkinly in follicular lymphoma
- Meta addresses India's accusations over exploitive ads
- SEC forms working group to combat retail investor fraud
- DeekSeek reportedly developing own AI chip to reduce reliance on Nvidia, Huawei
- CleanSpark continues to see highest SI among firms with mcap above $2B in June
- Governance Veteran Ken Bertsch Joins Anteris Advisors as Senior Advisor